Genprex

Reprogramming the course of cancer and diabetes

Technologies

Our technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options.

Pipeline

We are developing gene therapies for patients with cancer and diabetes to bring new therapies to large patient populations. Our lead product candidate, REQORSA™ immunogene therapy, is designed to be administered in combination with other therapies, including targeted therapies and immunotherapies, for non-small cell lung cancer.

Management Team

We have assembled a multidisciplinary team of executives and advisors with broad business experience in the biotech and pharmaceutical industries, and research and clinical experience at preeminent medical and academic institutions around the world. Our management team pairs an unmatched expertise with a knack for innovation in research.

Learn More

About Us


At Genprex, we are committed to developing life-changing gene therapies for patients with cancer and diabetes through unique, innovative science. We are dedicated in our efforts to helping patients with limited or no treatment options to have access to new and advanced therapies to more effectively treat their disease. 

What they’re saying

In the Media


Catch up with our

Latest News


Genprex to Present at Upcoming June Investor Conferences

Corporate Presentation to Highlight Company’s Gene Therapies for Cancer and Diabetes

Genprex to Present at Upcoming Investor Conference in May 2022

Corporate Presentation to Highlight Company’s Gene Therapies for Cancer and Diabetes

Genprex’s Chief Medical Officer to Be Featured as an Expert Panelist at the 33rd Annual Cancer Progress Conference

Live panel discussion will explore considerations with respect to positioning of cell-based and other emerging immunotherapy platforms in solid tumors

Genprex Issues Shareholder Letter and Provides 2022 Corporate Update

Company achieves major milestones in clinical development programs in 2022

Patient treatment in Acclaim-2 clinical trial commences